Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, October 22, 2014
Technology Networks
 
Register | Sign in
Home Page>News

  News Archive

QIAGEN, Lilly form CDx Collaboration
Friday, May 30, 2014
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.

Novacyt, Lab21 to Combine in Stock-For-Stock Transaction
Wednesday, May 28, 2014
On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.

Transgenomic Licenses Exclusive Rights to Multiplexed Ice Cold-PCRTM Technology
Wednesday, May 28, 2014
Multiplexed Version of Revolutionary Technology Enables Efficient Detection of Multiple Cancer Mutations in a Single Liquid Assay

FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Tuesday, May 27, 2014
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.

TriLink to Open New Early Phase Therapeutic Manufacturing Facility
Tuesday, May 27, 2014
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.

OncoCyte Corporation, Cornell University License Agreement to Accelerate Lung Cancer Diagnostic Product Development
Tuesday, May 27, 2014
PanC-Dx™ Markers to be Tested in Patient Samples Collected by Investigators at Weill-Cornell Medical Center.

Pacific Edge Signs Cxbladder Agreement with MultiPlan
Sunday, May 25, 2014
The agreement is another step in the Company’s commercial roll-out of Cxbladder in the United States, the world’s largest healthcare market.

FDA Approve Immucor MDx Test
Friday, May 23, 2014
PreciseType™ HEA test becomes the first-ever FDA-approved diagnostic for molecular typing of donor and recipient red blood cells for blood transfusions.

Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Friday, May 23, 2014
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.

<< 9 10 11 12 13 14 15 >>
Showing Results 111 - 120 of 1466
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv